Enzolytics Inc. (ENZC)
USD 0.0
(7.69%)
USD 0.0
(7.69%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.17 Million USD | -24.38% |
| 2022 | 2.88 Million USD | 81.22% |
| 2021 | 1.59 Million USD | -51.61% |
| 2020 | 3.28 Million USD | 409.2% |
| 2019 | 645.4 Thousand USD | -61.92% |
| 2018 | 1.69 Million USD | 540.05% |
| 2017 | 264.81 Thousand USD | 484.7% |
| 2016 | 45.29 Thousand USD | -99.1% |
| 2015 | 5.02 Million USD | 0.0% |
| 2010 | 2.91 Million USD | 206.49% |
| 2009 | 950.12 Thousand USD | 135.76% |
| 2008 | 402.99 Thousand USD | 833.41% |
| 2007 | 43.17 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 167.19 Thousand USD | 0.0% |
| 2024 Q2 | -22.06 Thousand USD | -113.2% |
| 2023 Q3 | 2.32 Million USD | 81.44% |
| 2023 FY | 2.17 Million USD | -24.38% |
| 2023 Q1 | 412.77 Thousand USD | -55.17% |
| 2023 Q2 | 1.28 Million USD | 210.53% |
| 2022 Q2 | 769.97 Thousand USD | -6.74% |
| 2022 FY | 2.88 Million USD | 81.22% |
| 2022 Q4 | 920.75 Thousand USD | 153.38% |
| 2022 Q3 | 363.38 Thousand USD | -52.81% |
| 2022 Q1 | 825.66 Thousand USD | 0.0% |
| 2021 FY | 1.59 Million USD | -51.61% |
| 2021 Q1 | 559.86 Thousand USD | -38.79% |
| 2021 Q2 | 393.89 Thousand USD | -29.65% |
| 2021 Q3 | 370.21 Thousand USD | -6.01% |
| 2020 Q4 | 914.73 Thousand USD | 0.0% |
| 2020 FY | 3.28 Million USD | 409.2% |
| 2019 FY | 645.4 Thousand USD | -61.92% |
| 2018 FY | 1.69 Million USD | 540.05% |
| 2017 FY | 264.81 Thousand USD | 484.7% |
| 2016 FY | 45.29 Thousand USD | -99.1% |
| 2015 FY | 5.02 Million USD | 0.0% |
| 2011 Q1 | 253.77 Thousand USD | -68.54% |
| 2011 Q2 | 229.37 Thousand USD | -9.61% |
| 2010 Q1 | 518.01 Thousand USD | -14.95% |
| 2010 FY | 2.91 Million USD | 206.49% |
| 2010 Q4 | 806.54 Thousand USD | 27.43% |
| 2010 Q3 | 632.94 Thousand USD | 94.74% |
| 2010 Q2 | 325.02 Thousand USD | -37.26% |
| 2009 Q3 | 197.68 Thousand USD | 121.08% |
| 2009 Q1 | 53.94 Thousand USD | -55.03% |
| 2009 Q2 | 89.41 Thousand USD | 65.76% |
| 2009 Q4 | 609.07 Thousand USD | 208.1% |
| 2009 FY | 950.12 Thousand USD | 135.76% |
| 2008 Q4 | 119.96 Thousand USD | -26.35% |
| 2008 Q2 | 18.1 Thousand USD | 2.84% |
| 2008 FY | 402.99 Thousand USD | 833.41% |
| 2008 Q3 | 162.88 Thousand USD | 799.92% |
| 2008 Q1 | 17.6 Thousand USD | 167.45% |
| 2007 Q3 | 1561.00 USD | 0.0% |
| 2007 FY | 43.17 Thousand USD | 0.0% |
| 2007 Q4 | -26.09 Thousand USD | -1771.68% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -63.206% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 56.773% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 92.625% |
| Nascent Biotech, Inc. | 2.22 Million USD | 2.259% |
| Rebus Holdings, Inc. | 664 Thousand USD | -228.239% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 94.15% |
| Qrons Inc. | 643.67 Thousand USD | -238.603% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -459.471% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.206% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -424.577% |
| Skye Bioscience, Inc. | 13.54 Million USD | 83.912% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.489% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 55.682% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -732.744% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.454% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 25.263% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -45.117% |
| Mesoblast Limited | 5.9 Million USD | 63.072% |
| Marizyme, Inc. | 19.23 Million USD | 88.672% |
| Genus plc | 147.7 Million USD | 98.524% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 75.174% |
| Pharming Group N.V. | 225.49 Million USD | 99.033% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -6.385% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -62.462% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 73.864% |
| ContraFect Corporation | 56.88 Million USD | 96.169% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 50.563% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -47.388% |
| IMV Inc. | 37.7 Million USD | 94.22% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 21.891% |
| MultiCell Technologies, Inc. | 567.42 USD | -384008.244% |
| ONE Bio Corp. | 6.44 Million USD | 66.177% |
| Accustem Sciences Inc. | 3.74 Million USD | 41.824% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.464% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -309.711% |
| Q BioMed Inc. | 3.43 Million USD | 36.58% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 91.181% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 17.051% |
| Biomind Labs Inc. | 994.18 Thousand USD | -119.226% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.806% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -23.858% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 67.557% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -16.903% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 8818.028% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 86.387% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -18.768% |
| GB Sciences, Inc. | 1.42 Million USD | -53.431% |
| Alpha Cognition Inc. | 9.7 Million USD | 77.544% |
| HST Global, Inc. | 140.9 Thousand USD | -1446.77% |
| CSL Limited | 3.44 Billion USD | 99.937% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -93.749% |
| Halberd Corporation | 74.84 Thousand USD | -2812.144% |
| Agentix Corp. | 1.37 Million USD | -58.884% |
| Resverlogix Corp. | 12.71 Million USD | 82.855% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 40.299% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.858% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -108.765% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 9.374% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -38.0% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 35.991% |
| AVAX Technologies, Inc. | 7.31 Million USD | 70.186% |
| Zenith Capital Corp. | 8.94 Million USD | 75.629% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.736% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -12410.803% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 11.233% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1170.783% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -13.462% |
| Kadimastem Ltd | 2.41 Million USD | 9.568% |
| Helix BioMedix, Inc. | 1.97 Million USD | -10.521% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 79.944% |
| BioStem Technologies, Inc. | 22.97 Million USD | 90.513% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1100.93% |
| LadRx Corporation | 3.81 Million USD | 42.822% |
| Cell Source, Inc. | 4.32 Million USD | 49.611% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -136.003% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -136.003% |
| NovAccess Global Inc. | 2.46 Million USD | 11.645% |
| Affymax, Inc. | 39.38 Million USD | 94.466% |
| Itoco Inc. | 919.14 Thousand USD | -137.124% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 48.577% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -94.773% |
| Mobile Lads Corp. | 554.54 Thousand USD | -293.025% |
| CytoDyn Inc. | 18.05 Million USD | 87.931% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -8559.49% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -890.334% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -53.509% |
| SYBLEU INC | 160.87 Thousand USD | -1254.774% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -19.996% |
| International Stem Cell Corporation | 5.27 Million USD | 58.651% |
| Bioxytran, Inc. | 3.82 Million USD | 42.947% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4040.244% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -10613.793% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.99% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -34.704% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -196.195% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 29.942% |
| Neutra Corp. | 243.82 Thousand USD | -793.896% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 87.515% |
| PureTech Health plc | 144.59 Million USD | 98.493% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 89.363% |
| IXICO plc | 4.7 Million USD | 53.696% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 75.224% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.149% |
| CSL Limited | 3.89 Billion USD | 99.944% |
| Cellectis S.A. | 97.32 Million USD | 97.76% |